Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Veru Inc chart...

About the Company

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries

CEO

Mitchell Steiner

Exchange

NASDAQ

Website

https://verupharma.com/

$15M

Total Revenue

72

Employees

$52M

Market Capitalization

-0.42

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VERU News

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

6d ago, source:

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)

1mon ago, source: Hosted on MSN

Veru Inc. (VERU) has been on a downward spiral lately with significant selling pressure. After declining 15.6% over the past four weeks, the stock looks well positioned for a trend reversal as it ...

Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

1mon ago, source: Hosted on MSN

T he market expects Veru Inc. (VERU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus ...

Veru Inc

6d ago, source: Morningstar

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss ...

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

20d ago, source: Business Insider

MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher ...

Client Profile: Veru Inc

27d ago, source: OpenSecrets.org

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...

Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript

1mon ago, source: Yahoo Finance

Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript February 8, 2024 Veru Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Veru Announces New Scientific Advisory Board For Its Enobosarm Program For High Quality Weight Loss

28d ago, source: Mena FN

(MENAFN- GlobeNewsWire - Nasdaq) MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

VERU Mar 2024 0.500 put

2d ago, source: Yahoo Finance

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality ...

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

6d ago, source: Morningstar

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high ...

Veru Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...